Cargando…

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults

Type 2 diabetes affects millions of people worldwide and significantly contributes to morbidity and mortality of those affected by it. Current guidelines recommend individualized treatment regimens following first line metformin therapy. Saxagliptin, a dipeptidyl-peptidase 4 inhibitor, provides a se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minze, Molly G., Klein, Mary S., Terrell, Brian T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738378/ https://www.ncbi.nlm.nih.gov/pubmed/23966808 http://dx.doi.org/10.4137/CMED.S8510

Ejemplares similares

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
por: Panagoulias, George S, et al.
Publicado: (2014)

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2011)

Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
por: Irons, Brian K, et al.
Publicado: (2014)

Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Barnard, Karen, et al.
Publicado: (2010)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Reynolds, Jonathan K
Publicado: (2009)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview
por: Davidson, Jaime A., et al.
Publicado: (2016)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
por: Moses, Robert
Publicado: (2009)

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
por: Elgart, Jorge F, et al.
Publicado: (2013)

Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes
por: Sharma, Morali D
Publicado: (2010)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
por: Cobble, Michael E, et al.
Publicado: (2012)

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Kulasa, Kristen, et al.
Publicado: (2010)

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients
por: Konya, Hiroyuki, et al.
Publicado: (2014)

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
por: Jain, Rajeev
Publicado: (2015)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
por: White, Judith L, et al.
Publicado: (2014)

Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
por: Johansson, Lars, et al.
Publicado: (2020)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
por: Farr, Amanda M, et al.
Publicado: (2016)

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
por: Minze, Molly G, et al.
Publicado: (2016)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu, Huan, et al.
Publicado: (2017)

Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
por: Fleming, Joshua W, et al.
Publicado: (2015)

Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
por: Ballav, Chitrabhanu, et al.
Publicado: (2013)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz, Baptist
Publicado: (2010)

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
por: Neumiller, Joshua J.
Publicado: (2014)

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2020)

Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia
por: Bekele, Mengistu, et al.
Publicado: (2021)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
por: Neutel, Joel M., et al.
Publicado: (2013)

Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects
por: Vakkalagadda, Blisse, et al.
Publicado: (2016)

Clinical outcomes, not clinical utility, should be the major consideration for saxagliptin with or without metformin
por: Doggrell, Sheila A
Publicado: (2014)

Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes
por: Edwards, Krystal L, et al.
Publicado: (2015)

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
por: Dave, Darshan J.
Publicado: (2011)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Liu, Hao, et al.
Publicado: (2016)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
por: Ott, Christian, et al.
Publicado: (2014)

Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment
por: Tao, Tao, et al.
Publicado: (2018)

Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review
por: Kedia, Rohit, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ra3cp0nb902qbnlirrr548uqc8